About this trial
This study looks at a new way to treat children with high-risk neuroblastoma. The focus is on a treatment called N10 chemotherapy. Researchers want to find out if this treatment is safe and effective for young patients with this type of cancer.
This study is known as NCT06528496. It is a Phase 2 trial, which means it is looking at how well the treatment works and how safe it is. The study is FDA-regulated and aims to include about 45 participants.
Who can join
This trial is open to children aged 18 months to 19 years, both boys and girls. To join, they need a diagnosis of high-risk neuroblastoma. They should not have had more than one cycle of high-risk neuroblastoma chemotherapy. The team will check eligibility to confirm who can join.
Conditions
High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma
The study team makes the final call on eligibility.
What happens in the study
Participants in the trial will receive four cycles of induction chemotherapy. After that, their treatment will depend on how they respond. They will receive various medicines, including a special antibody treatment and other chemotherapy drugs.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
Memorial Sloan Kettering Cancer Center
New York, New York